MD
Pediatrix Medical Group, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $58.2M | the 2026 first quarter | — |
|
|
|||
| Adjusted EPS non-GAAP | $0.44 | the first quarter of 2026 | — |
| Same-unit revenue attributable to patient volume | -1.6% | the three months ended March 31, 2026 | — |
| Same-unit revenue from net reimbursement-related factors | 4.4% | the three months ended March 31, 2026 | — |
| Same-unit revenue growth | 2.8% | the three months ended March 31, 2026 | — |
| accounts receivable DSO | 42.5 | Q1 2026 call | — |
| capital deployed for share repurchases | $21M | Q1 2026 call | — |
| net non-same-unit activity | $6M | Q1 2026 call | — |
| NICU days change | -1% | Q1 2026 call | — |
| operating cash flow | -$130M | Q1 2026 call | — |
| practice-level S, W, and B expenses increase | $9M | Q1 2026 year over year call | — |
| pricing growth | 4% | Q1 2026 call | — |
| shares outstanding | 82M | Q1 2026 call | — |
| shares repurchased | 1M | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MD
this stock
Pediatrix Medical Group, Inc.
|
$2.21B | +25.2% | — | 13.1 | 4.6% |
|
HCA
HCA Healthcare, Inc.
|
$90.73B | -11.9% | +7.1% | 14.1 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.28B | -14.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.81B | +3.8% | -2.3% | 10.8 | 4.7% |
|
DVA
Davita Inc.
|
$14.73B | +103.1% | +6.5% | 21.4 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MD | +5.8% | +19.2% | +20.8% | +5.8% | +25.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +5.9% | +18.4% | +13.4% | +5.9% | +15.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.